Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y. Yamamura J, et al. Among authors: yoshidome k. Chemotherapy. 2017;62(5):307-313. doi: 10.1159/000475879. Epub 2017 Jun 13. Chemotherapy. 2017. PMID: 28605730 Clinical Trial.
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group. Taguchi T, et al. Among authors: yoshidome k. Chemotherapy. 2010;56(2):166-70. doi: 10.1159/000313531. Epub 2010 Apr 21. Chemotherapy. 2010. PMID: 20407245 Clinical Trial.
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Taguchi T, Yamamoto D, Masuda N, Oba K, Nakayama T, Nagata T, Nomura M, Yoshidome K, Yoshino H, Matsunami N, Miyashita M, Furuya Y, Ishida T, Wakita K, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Taguchi T, et al. Among authors: yoshidome k. Cancer Chemother Pharmacol. 2013 Mar;71(3):741-7. doi: 10.1007/s00280-012-2068-7. Epub 2013 Jan 20. Cancer Chemother Pharmacol. 2013. PMID: 23334260 Clinical Trial.
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K, Iwamoto M, Tanaka S, Yamamoto D, Yoshidome K, Ogura H, Terasawa R, Matsunami N, Takahashi Y, Nitta T, Morimoto T, Fujioka H, Kawaguchi K, Uchiyama K. Kimura K, et al. Among authors: yoshidome k. Cancer Chemother Pharmacol. 2018 May;81(5):923-933. doi: 10.1007/s00280-018-3567-y. Epub 2018 Mar 28. Cancer Chemother Pharmacol. 2018. PMID: 29594360 Clinical Trial.
Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Tanaka S, et al. Among authors: yoshidome k. Clin Breast Cancer. 2015 Jun;15(3):191-6. doi: 10.1016/j.clbc.2014.12.003. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25579459 Clinical Trial.
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214.
Masuda N, Yoshinami T, Ikeda M, Mizutani M, Yamaguchi M, Komoike Y, Takashima T, Yoshidome K, Tsurutani J, Iwamoto M, Fujisawa F, Yasojima H, Yamamura J, Morishima H, Aki F, Yamada T, Morita S, Nakayama T. Masuda N, et al. Among authors: yoshidome k. Cancers (Basel). 2021 Aug 31;13(17):4399. doi: 10.3390/cancers13174399. Cancers (Basel). 2021. PMID: 34503209 Free PMC article.
The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S. Kim SJ, et al. Among authors: yoshidome k. Cancer Lett. 2014 Dec 28;355(2):217-23. doi: 10.1016/j.canlet.2014.08.042. Epub 2014 Sep 10. Cancer Lett. 2014. PMID: 25218592
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay.
Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S, Mano M, Masuda N, Takeda M, Tsujimoto M, Yoshidome K, Inaji H, Nakajima H, Komoike Y, Kataoka TR, Nakamura S, Suzuki K, Tsugawa K, Wakasa K, Okino T, Kato Y, Noguchi S, Matsuura N. Tamaki Y, et al. Among authors: yoshidome k. Clin Cancer Res. 2009 Apr 15;15(8):2879-84. doi: 10.1158/1078-0432.CCR-08-1881. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351770
62 results